Insights

Our Insights series brings you perspectives on biosimilars from key leaders in the field.

EP. 1: Available Oncology Biosimilars and Their Efficacy

EP. 2: What Are Biosimilars?

EP. 3: Are Biosimilars and Biologics Similar?

EP. 4: Can Biosimilars Be Switched?

EP. 5: The FDA Approval of Biosimilars

EP. 6: The FDA Pathway for Interchangeable Biosimilars

EP. 7: Deciding Which Biosimilar to Use

EP. 8: How Biosimilars Have Impacted Cancer Treatment

EP. 9: Patient Access to Biosimilars

EP. 10: The Economic Impact of Biosimilars

EP. 11: The Role of Insurance Companies and PBMs on Biosimilar Access

EP. 12: Formulary Inclusion for Biosimilars

EP. 13: Biosimilar Challenges for Providers and Payers

EP. 14: Educating Patients and Clinicians About Biosimilars

EP. 1: Comparison of Biologics to Biosimilars Versus Generics

EP. 2: The BPCIA and the Naming of Biosimilars

EP. 3: The Approval Process for Biosimilars

EP. 4: Considerations for Approving Generics Versus Biosimilars

EP. 5: Interchangeability and Postmarketing Pharmacovigilance of Biosimilars

EP. 6: Experience Prescribing Biosimilars Versus Biologics

EP. 7: The Impact of Access to Biosimilars

EP. 8: US and EU Biosimilar Pricing and Stakeholder Education

EP. 9: Formulary Approval and Challenges for Payers

EP. 10: Prescribing Biosimilars and Educating Patients and Physicians

EP. 11: The Influence of Biosimilars in Cancer Care

EP. 12: Biosimilars in the Pipeline and Disease Management

EP. 13: Outlook on the Future of Biosimilars